FUNDAMENTALS |
MarketCap: |
12 431 mill
|
EPS: |
8.86
|
P/E: |
45.62
|
Earnings Date: |
Apr 21, 2024 |
SharesOutstanding: |
30.76 mill
|
Avg Daily Volume: |
0.251 mill
|
RATING
2024-03-28 |
S
|
Strong Buy
|
RATINGS |
Rating CashFlow: |
Buy
|
|
Return On Equity: |
Strong Buy
|
|
Return On Asset: |
Strong Buy
|
|
DE: |
Strong Buy
|
|
P/E: |
Strong Buy
|
|
Price To Book: |
Strong Buy
|
|
QUARTER GROWTHS |
|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 |
Revenue | | | | | | |
Gr.Profit | | | | | | |
Ebit | | | | | | |
Asset | | | | | | |
Debt | | | | | | |
PE RATIO: COMPANY / SECTOR |
0.00x
|
Company: PE 45.62 | sector: PE -3.05
|
PE RATIO: COMPANY / INDUSTRY |
2.44x
|
Company: PE 45.62 | industry: PE 18.71
|
DISCOUNTED CASH FLOW VALUE |
$403.44
(-0.17%)
$-0.707
|
Date: 2024-03-29
|
Expected Trading Range (DAY) |
$ 392.95 - 415.36
( +/- 2.77%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2024-03-15 | Burwig Susan E | Sell | 102 | Common Stock |
2024-03-14 | Keating Ashley M. | Sell | 500 | Stock Option (Right to Buy) |
2024-03-14 | Keating Ashley M. | Buy | 500 | Common Stock |
2024-03-14 | Keating Ashley M. | Sell | 250 | Common Stock |
2024-03-06 | Troendle August J. | Sell | 100 000 | Common Stock |
INSIDER POWER |
-94.81
|
Last
100 transactions |
Buy:
68 870 | Sell:
2 664 955 |
Forecast:
16:00 - $404.51
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $404.51
Forecast 2: 16:00 - $404.51
Forecast 3: 16:00 - $404.51
SCORE
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
MACD |
|
Volume Signals |
Price |
$404.15 (0.22% )
|
Volume |
0.170 mill
|
Avg. Vol. |
0.251 mill
|
% of Avg. Vol |
67.42 %
|
Signal 1: |
|
Signal 2: |
|
Last 10 Buy & Sell Signals For MEDP
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date |
Signal |
@ |
Closed |
% |
Feb 8 - 15:35 | buy | $318.05 | N/A | Active |
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.